Diabetic cardiomyopathy: Ongoing controversies in 2012

Herz

Volumn 37, Issue 8, 2012, Pages 880-886

  Seferovic P M ^a,b   Milinkovic I ^a   Ristic A D ^a   Seferovic Mitrovic J P ^a   Lalic K ^a   Jotic A ^a   Kanjuh, V ^b   Lalic N ^a,b   Maisch, B ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SERBIAN ACADEMY OF SCIENCES AND ARTS   (Serbia)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cardiac autonomic neuropathy; Diabetes mellitus; Diabetic cardiomyopathy; Heart failure; Left ventricular dysfunction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ALDOSTERONE ANTAGONIST; AMINOGUANIDINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTIAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARNITINE; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ARTICLE; AUTONOMIC DYSFUNCTION; BODY MASS; CARNITINE DEFICIENCY; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DIET THERAPY; DIZZINESS; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); METABOLIC DISORDER; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSICAL ACTIVITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; BIOLOGICAL MODEL; HEART LEFT VENTRICLE FUNCTION; SYNDROME;

DIABETIC CARDIOMYOPATHIES; HEART FAILURE; HUMANS; MODELS, CARDIOVASCULAR; SYNDROME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878017726     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3720-z     Document Type: Article

References (86)

1. Consentino F, Ryden L, Francia P (2006) Diabetes mellitus and metabolic syndrome. In: Camm AJ, Luscher TF, Serruys PW (eds) The ESC Textbook of cardiovascular medicine, Blackwell, London, p 301-331
2. Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28(1):88-136
3. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038
4. Iribarren C, Karter AJ, Go AS et al (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668-2673
5. Bertoni AG, Goff DC Jr, D'Agostino RB Jr et al (2006) Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 29(3):588-594
6. Rubler S, Dlugash J, Yuceoglu YZ et al (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595-602
7. Bell DSH (2003) Diabetic cardiomyopathy. Diabetes Care 26:2949-2951
8. Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 29(2):270-276
9. Maron BJ (2008) Controversies in heart failure. The 2006 American Heart Association classification of cardiomyopathies is the gold standard. Circ Heart Fail 1:72-76
10. Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11:31-39
11. Maisch B, Alter P, Pankuweit S (2011) Diabetic cardiomyopathy-fact or fiction. Herz 36:102-117
12. Khavandi K, Khavandi A, Asghar O et al (2009) Diabetic cardiomyopathy-a distinct disease? Best Pract Res Clin Endocrinol Metab 23(3):347-360
13. Fang ZY, Yuda S, Anderson V et al (2003) Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 41:611-617
14. Di Bonito P, Cuomo S, Moio N et al (1996) Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabet Med 13:321-324
15. Redfield MM, Jacobsen SJ, Burnett JC et al (2003) Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 289:194-202
16. Seferovic Mitrovic JP, Seferovic PM, Vujisic Tešic B et al (2012) Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes. In J Cardiol 156:219-221
17. Paulus WJ, Tschöpe C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539-2550
18. Struthers AD, Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430-1432
19. Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodelling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239-247
20. Phillips RA, Krakoff LR, Dunaif A et al (1998) Relation among left ventricular mass, insulin resistance and blood pressure in non obese subjects. J Clin Endocrinol Metab 83:4284-4288
21. Braz JC, Gregory K, Pathak A et al (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nature Medicine 10(3):248-254
22. Aneja A, Tang WH, Bansilal S et al (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121:748-757
23. Seddon M, Looi YH, Shah AM (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93(8):903-907
24. Chiu J, Farhangkhoee H, Xu BY et al (2008) PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 45(3):385-393
25. Fiordaliso F, Leri A, Cesselli D et al (2001) Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50:2363-2375
26. Argirova MD, Ortwerth BJ (2003) Activation of protein-bound copper ions during early glycation: study on two proteins. Arch Biochem Biophys 420:176-184
27. Rutter MK, Parise H, Benjamin EJ et al (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107:448-454
28. Voulgari C, Moyssakis I, Papazafiropoulou A et al (2010) The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev 26:121-127
29. Paternostro G, Pagano D, Gnecchi-Ruscone T et al (1999) Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 42:246-253
30. Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E (1999) Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications 13:86-90
31. Sunni S, Bishop SP, Kent SP, Geer JC (1986) Diabetic cardiomyopathy. A morphological study of intramyocardial arteries. Arch Pathol Lab Med 110:375-381
32. Manzella D, Barbieri M, Rizzo MR et al (2001) Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab 86:2769-2774
33. Garay-Sevilla ME, Nava LE, Malacara JM et al (2000) Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 16:106-113
34. Seferovic PM, Ristic AD, Maksimovic R (2002) Progression of myocarditis to dilated cardiomyopathy: Role of the adrenergic system and myocardial catecholamines. In: Cooper L (ed) Myocarditis: from bench to bedside, Humana, New Jersey p 215-230
35. Kurata C, Okayama K, Wakabayashi Y et al (1997) Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozocin-induced diabetic rats. J Nucl Med 38:1677-1680
36. Stevens MJ, Raffel DM, Allman KC et al (1998) Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98:961-968
37. Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101:2271-2276
38. Maciver DH, Townsend M (2008) A novel mechanism of heart failure with normal ejection fraction. Heart 94:446-449
39. Tschöpe C, Lam CSP (2012) Diastolic heart failure: what we still don't know? Looking for new concepts, diagnostic approaches and the role of co-morbidities. Herz (Verlag bitte einsetzen
40. Pankuweit S, Ruppert V, Maisch B (2004) Inflammation in dilated cardiomyopathy. Herz 29(8):788-793
41. Simone G de, Devereux RB, Chinali M et al (2009) Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the strong heart study. Nutr Metab Cardiovasc Dis 19:98-104
42. Van Heerebeek L, Hamdani N, Handoko ML et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43-51
43. Ma H, Li AY, Xu P et al (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) upregulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13(8B):1751-1764
44. Giardino I, Fard AK, Hatchell DL, Brownlee M (1998) Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47(7):1114-1120
45. Arnold JM, Yusuf S, Young J et al (2003) Prevention of heart failure in patients in the Heart Outcome Prevention Evaluation (HOPE) study. Circulation 107:1284-1290
46. Seferovic PM, Ristic A, Maksimovic R et al (2003) The natural history of viral myocarditis: pathogenetic role of adrenergic system dysfunction in the development of idiopathic dilated cardiomyopathy. In: Matsumori A (ed) Cardiomyopathies and heart failure: biomolecular, infectious and immune mechanisms, Kluwer Academic Publishers, Dordrecht, p 358-372
47. Russell RR, Yin R, Caplan MJ et al (1998) Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation 98:2180-2186
48. Stevens MJ, Raffel DM, Allman KC et al (1998) Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98:961-968
49. Nakano S, Kitazawa M, Ito T, Hatakeyama H et al (2003) Insulin resistant state in type 2 diabetes is related to advanced autonomic neuropathy. Clin Exp Hypertens 25:155-167
50. Maisch B, Rupp H. Myocardial fibrosis: a cardiopathophysiologic Janus head. Herz 2006;31(3):260-268
51. Schannwell CM, Schneppenheim M, Perings S et al (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98:33-39
52. Ziegler D, Weise F, Langen KJ et al (1998) Effect of glycaemic control on myocardial sympathetic innervation assessed by (123I) metaiodo-benzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 41:443-451
53. Schnell O, Muhr D, Dresel S et al (1997) Partial restoration of scintigraphically assessed cardiac sympatethic denervation in newly diagnosed patients with insulin dependent (type 1) diabetes mellitus at one-year follow-up. Diabet Med 14:57-62
54. Hansen A, Johansson BL, Wahren J, Bibra H von (2002) C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 51:3077-3082
55. Norby FL, Wold LE, Duan J, Hintz KK, Ren J (2002) IGF-1 attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes. Am J Physiol Endocrinol Metab 283:E658-E666
56. Maisch B (2006) Obesity, diabetes mellitus and metabolic syndrome: the implications for heart and the vascular system. Herz 31(3):185-188
57. Stolar MW (2002) Insulin resistance, diabetes, and the adipocyte. Am J Health Syst Pharm 59(Suppl 9):S3-S8
58. Pavo I, Jermendy G, Varkonyi TT et al (2003) Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88:1637-1645
59. Taegtmeyer H (2004) Cardiac metabolism as a target for the treatment of heart failure. Circulation 110:894-896
60. Hammer S, Meer RW van der, Lamb HJ et al (2008) Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 90413
61. Rodrigues B, Camm MC, Mcneill GH (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180:53-57
62. Hall JL, Sexton WL, Stanley WC (1995) Exercise training attenuates the reduction of myocardial GLUT-4 in diabetic rats. J Appl Physiol 78:76-81
63. Osborn BA, Daar JT, Laddaga RA et al (1997) Exercise training increases sarcolemmal GLUT-4 protein and mRNA content in diabetic heart. J Appl Physiol 82:828-834
64. DeBlieux PM, Barbee RW, McDonough KH, Shepard RE (1993) Exercise training improves cardiac performance in diabetic rats. Proc Soc Exp Biol Med 203:209-213
65. Ramasubbu K, Estep J, White DL et al (2008) Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51(4):415-426
66. Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22):2248-2261 (see comment
67. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Erratum appears in Lancet 1999;354(9178):602. Lancet 352(9131):837-853
68. Jarnert C, Landstedt-Hallin L, Malmberg K et al (2009) A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus and Diastolic Dysfunction) study. Eur J Heart Fail 11(1):39-47
69. Flather MD, Shibata MC, Coats AJ et al (2005) Randomised trial to deter-mine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225
70. The Capricorn Investigators (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the Capricorn randomized study. Lancet 357:1385-1390
71. Fonseca V, Bakris GL, Bell DS et al (2007) GEMINI Investigators. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 24:759-763
72. Boer RA de, Doehner W, Horst IC van der SENIORS Investigators et al (2010) Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or = 70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 106(1):78-86
73. Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
74. Arbustini E, Cecchi F, Seferovic PM et al (2002) The need for European Registries in inherited cardiomyopathies. Eur Heart J 23(24):1972-1974
75. Mitrovic V, Seferovic PM, Simeunovic D et al (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27(23):2823-2832
76. Mitrovic V, Willenbrock R, Seferovic PM et al (2003) Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neuro-hormones, and clinical symptoms in patients with congestive heart failure. Am Heart J 145(3):E14
77. Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053-1059
78. Henriksen EJ, Jacob S, Kinnikck TR et al (1999) ACE inhibition and glucose transport in insulin resist-ant muscle: roles of bradykinin and nitric oxide. Am J Physiol 277:R332-R336
79. Hermann F, Ruschitzka FT, Schiffrin EL (2004) Clinical trials report. CHARM-Preserved Trial. Curr Hypertens Rep 6(1):48-50 (No abstract available
80. Zile MR, Gaasch WH, Anand IS et al (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 121(12):1393-1405
81. Werner CM, Bohm M (2008) Review: the therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis 2(3):167-177
82. Yaras N, Bilginoglu A, Vassort G et al (2007) Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol 292(2):H912-H920
83. Afzal N, Pierce GN, Elimban V et al (1989) Influence of verapamil on some subcellular defects in diabetic cardiomyopathy. Am J Physiol 256:E453-E458
84. Shah TS, Satia MC, Gandhi TP et al (1995) Effects of chronic nifedipine treatment on streptozocin-induced diabetic rats. J Cardiovasc Pharmacol 26:6-12
85. Pieske BA, Wachter RB (2008) Impact of diabetes and hypertension on the heart. Current Opinion in Cardiology 23(4):340-349
86. Tribouilloy C, Rusinaru D, Mahjoub H et al (2008) Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective 5-year study. Heart 94(11):1450-1455